Removing hepatitis C antibody testing for Australian blood donations: A cost‐effectiveness analysis

The risk of transfusion‐transmitted hepatitis C virus (HCV) infections is extremely low in Australia. This study aims to conduct a cost‐effectiveness analysis of different testing strategies for HCV infection in blood donations.

[1]  V. Hoad,et al.  Is dual testing for hepatitis C necessary? Modelling the risk of removing hepatitis C antibody testing for Australian blood donations , 2023, Vox sanguinis.

[2]  Z. Ivics,et al.  Second hepatitis C virus transmission by blood components since introduction of mandatory NAT screening in Germany , 2022, Transfusion.

[3]  Jisoo A. Kwon,et al.  Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications , 2021, PloS one.

[4]  N. Mitsakakis,et al.  A Systematic Review and Meta-Analysis of Health Utilities in Patients With Chronic Hepatitis C. , 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[5]  Jisoo A. Kwon,et al.  Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study , 2018, Journal of viral hepatitis.

[6]  D. Liew,et al.  Real‐world outcomes of unrestricted direct‐acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience , 2018, Journal of viral hepatitis.

[7]  A. Hayward,et al.  Assessing hepatitis C spontaneous clearance and understanding associated factors—A systematic review and meta‐analysis , 2018, Journal of viral hepatitis.

[8]  L. Madsen,et al.  Liver-related morbidity and mortality in patients with chronic hepatitis C and cirrhosis with and without sustained virologic response , 2017, Clinical epidemiology.

[9]  B. Custer,et al.  Development of a web‐based application and multicountry analysis framework for assessing interdicted infections and cost‐utility of screening donated blood for HIV, HCV and HBV , 2017, Vox sanguinis.

[10]  M. Postma,et al.  Cost effectiveness of adding nucleic acid testing to hepatitis B, hepatitis C, and human immunodeficiency virus screening of blood donations in Zimbabwe , 2016, Transfusion.

[11]  J. Ratcliffe,et al.  Health-related quality of life measured using the EQ-5D–5L: South Australian population norms , 2016, Health and Quality of Life Outcomes.

[12]  M. Hellard,et al.  Cost‐effectiveness of treating chronic hepatitis C virus with direct‐acting antivirals in people who inject drugs in Australia , 2016, Journal of gastroenterology and hepatology.

[13]  S. Kleinman,et al.  Relative efficacy of nucleic acid amplification testing and serologic screening in preventing hepatitis C virus transmission risk in seven international regions , 2015, Transfusion.

[14]  Ross J. Harris,et al.  Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios. , 2014, Journal of hepatology.

[15]  T. Davidson,et al.  The cost‐effectiveness of introducing nucleic acid testing to test for hepatitis B, hepatitis C, and human immunodeficiency virus among blood donors in Sweden , 2011, Transfusion.

[16]  G. Bonsel,et al.  Survival after transfusion in the Netherlands , 2011, Vox sanguinis.

[17]  O. Reichard,et al.  Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden , 2006, Scandinavian journal of infectious diseases.

[18]  J. Wong,et al.  Cost‐effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States , 2004, Vox sanguinis.

[19]  I. Franklin.  Regarding ‘Including polymerase chain reaction in screening for hepatitis C virus RNA in blood donations is not cost‐effective’ by Loubière et al. , 2002, Vox sanguinis.

[20]  Arturo Pereira,et al.  A model of the health and economic impact of posttransfusion hepatitis C: application to cost‐effectiveness analysis of further expansion of HCV screening protocols , 2000, Transfusion.

[21]  B. Custer,et al.  Cost-effectiveness analysis: what it really means for transfusion medicine decision making. , 2009, Transfusion medicine reviews.